•
Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer) chip technology, has raised nearly RMB 100 million (USD 14.8 million) in a Series B2 financing round. The round was led by Qianrong Investment and included participation from Walden International. Funding UseProceeds from the funding…
•
Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product specifically designed for cancer patients. Branded as Oral Impact Su Yi Su, the product provides a non-inflammatory diet for individuals recovering from cancer treatment, containing arginine, fish oil, omega-3, and nucleotides in addition to standard…
•
Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online hospital sector to advance the company’s digital health strategies, despite regulatory hurdles and profitability challenges. Regulatory LandscapeHornstein, who will soon take over as Sanofi’s global digital division head, addressed new rules issued in March 2022…
•
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in a Phase I clinical study for its ketorolac for IV infusion (NTM-001), a non-opioid analgesic co-developed with US-based Neumentum Inc. Study DetailsThe Phase I study enrolled 16 healthy subjects, who have completed the 96-hour sample…
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has accepted a supplementary Biologic License Application (sBLA) for its HanBeiTai, a biosimilar of Roche’s Avastin (bevacizumab), for review. The application is intended for the treatment of recurrent glioblastoma (GBM). Drug ProfileHanBeiTai was first approved in…
•
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG: 9960) to advance precision diagnosis and treatment in blood tumors. The partnership aims to enhance educational activities, promote the concept of precision detection and treatment, and improve the accessibility and standardization of genetic testing for…
•
China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun Pharmaceutical Group Ltd (HKG: 1681) to acquire 238,056,948 shares at RMB 9.17 (USD 1.36) per share, valuing the transaction at approximately RMB 2.2 billion (USD 325 million). About Consun PharmaceuticalConsun Pharma, listed on the Hong…
•
China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab has demonstrated sustained neutralizing activity against the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. Study ResultsLive virus neutralization experiments conducted in the US showed that 14 days after dosing, the total plasma concentration of the combination…
•
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY Biopharma Co., Ltd, securing global rights to the latter’s tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) for intravitreal injection. Financial terms were not disclosed. Agreement DetailsThe deal encompasses…
•
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic…
•
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic partnership on July 24, with the inauguration of the “Roche Diagnostics-Topgen Innovation Center of Excellence” in Chongqing. Center OverviewThe innovation center comprises several key facilities:
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer agreement with the National Institute for Viral Disease Control and Prevention, China’s CDC. The deal grants Hybio licensed use of technical secrets related to peptide sequences for vaccine development. Agreement DetailsHybio will pay an upfront…
•
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a three-year partnership with Huawei Technologies Co., Ltd to explore the application of artificial intelligence (AI) in drug development. The collaboration will focus on macro and small molecule drug design, related diseases, and database development. Partnership…
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration (NMPA) has accepted a market filing from its non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd for a combination therapy of fulvestrant and piroxetine in advanced breast cancer. This marks Xuanzhu Bio’s first filing for an…
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme Corp. (MSD) has entered into a second licensing agreement, securing global development, manufacturing, and commercialization rights to an undisclosed investigational antibody drug conjugate (ADC) from Kelun’s pipeline. The deal includes an upfront payment of USD…
•
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus monoclonal antibody (mAb), has received clinical trial approval from the National Medical Products Administration (NMPA). Development and ResearchF61 was co-developed by Yang Xiaoming’s team with CNBG and Liang Mifang’s team from the Chinese Center for…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell therapy, announced plans to raise USD 250 million through a secondary public offering of American Depositary Shares (ADSs). Each ADS represents two ordinary shares. The underwriters have a 30-day option to purchase an additional USD…
•
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its CoolAdvantage applicator series, alongside its official market launch in China. Technology and FeaturesCoolSculpting utilizes a non-surgical process called cryolipolysis to target and reduce subcutaneous fat by cooling fat cells to…
•
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s Therapeutic Goods Administration (TGA) for its Hanquyou (trastuzumab injection, EU trade name: Zercepac). The drug will be marketed under the trade names Tuzucip and Trastucip to treat HER2-positive early breast cancer, HER2-positive locally advanced breast…
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, multi-center Phase Ib/II clinical study of its SHR-1802 combined with SHR-1316 for advanced solid tumors. Drug Profiles Global PD-L1 MarketGlobal PD-L1 products include AstraZeneca’s Tecentriq…